Nymox Pharmaceutical Announces New Positive Results At 5 Years After Single Treatment in Long Term Study of NX-1207 for Benign Prostatic Hyperplasia

HASBROUCK HEIGHTS, N.J., Feb. 24, 2009 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced new positive results from a long term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company's two initial 2003 Phase 1-2 studies of NX-1207. Patients treated with NX-1207 were followed-up on an unselected and as available basis and assessed for symptomatic improvement, treatment outcomes, and durability of efficacy 64 months after treatment.